광선각화증 치료 시장 규모, 점유율 및 동향 분석 보고서 : 치료법별, 약제 클래스별, 용도별, 지역별 및 부문별 예측(2026-2033년)

Actinic Keratosis Treatment Market Summary

The global actinic keratosis treatment market size was estimated at USD 7.02 billion in 2025 and is projected to reach USD 10.13 billion by 2033, growing at a CAGR of 4.86% from 2026 to 2033. This growth is driven by the increasing prevalence of actinic keratosis due to prolonged ultraviolet (UV) exposure and a growing aging population vulnerable to sun-related skin damage.

Rising awareness about early diagnosis of precancerous skin conditions and improved access to dermatology services are also supporting market expansion. In addition, advancements in topical therapies, photodynamic therapy technologies, and cryotherapy procedures, along with the availability of effective prescription medications, are further contributing to the market's steady growth.

Actinic keratosis is among the most common precancerous skin conditions, largely caused by prolonged exposure to ultraviolet (UV) radiation from sunlight or artificial sources. The increasing incidence, particularly among fair-skinned and aging populations, is significantly expanding the patient pool requiring treatment. For instance, in April 2024, Oxford University Press published a meta-analysis in the British Journal of Dermatology reporting a pooled global prevalence of 14% (95% CI: 14-15), with rates reaching 18% in tropical and temperate regions and 19% among individuals aged over 60 years. This growing disease burden is directly translating into higher demand for effective therapeutic interventions.

The market is also benefiting from increasing awareness and early diagnosis of skin disorders, supported by large-scale public health initiatives and screening programs. Governments and dermatology organizations are actively promoting early detection of skin lesions, encouraging individuals to seek timely medical consultation. For instance, in May 2024, the Skin Cancer Foundation reported that over 5 million skin cancer cases are diagnosed annually in the U.S., with 1 in 5 individuals expected to develop skin cancer by age 70, largely linked to UV exposure. Additionally, screening initiatives have proven effective in early identification; the American Academy of Dermatology reported in 2024 that its programs have screened over 2.9 million individuals, identifying more than 293,000 suspicious lesions. Such initiatives are significantly contributing to earlier diagnosis and treatment of actinic keratosis, thereby driving market growth.

Global Actinic Keratosis Treatment Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the actinic keratosis treatment market on the basis of therapy, drug class, end use, and region:

• Therapy Outlook (USD Million, 2021 - 2033)
• Topical
• Surgery
• Photodynamic Therapy
• Drug Class Outlook (USD Million; 2021 - 2033)
• Nucleoside Metabolic Inhibitor
• NSAIDs
• Immune Response Modifiers
• Photoenhancers
• Others
• End Use Outlook (USD Million,2021 - 2033)
• Hospitals
• Private Clinics
• Homecare
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Actinic Keratosis Treatment Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product Method
    • 1.1.1.2. Drug Class Segment
    • 1.1.1.3. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Actinic Keratosis Treatment Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Therapy Snapshot
• 2.3. Drug Class Snapshot
• 2.4. End Use Snapshot
• 2.5. Competitive Landscape Snapshot

Chapter 3. Actinic Keratosis Treatment Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
• 3.5. Market Restraint Analysis
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. Actinic Keratosis Treatment Market: Therapy Estimates & Trend Analysis

• 4.1. Global Actinic Keratosis Treatment Market: Therapy Dashboard
• 4.2. Global Actinic Keratosis Treatment Market: Therapy Movement Analysis
• 4.3. Global Actinic Keratosis Treatment Market by therapy, Revenue
• 4.4. Topical
  • 4.4.1. Topical market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Surgery
  • 4.5.1. Surgery market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Photodynamic Therapy
  • 4.6.1. Photodynamic Therapy market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Actinic Keratosis Treatment Market: Drug Class Estimates & Trend Analysis

• 5.1. Global Actinic Keratosis Treatment Market: Drug Class Dashboard
• 5.2. Global Actinic Keratosis Treatment Market: Drug Class Movement Analysis
• 5.3. Global Actinic Keratosis Treatment Market by Drug Class, Revenue
• 5.4. Nucleoside Metabolic Inhibitor
  • 5.4.1. Nucleoside Metabolic Inhibitor market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. NSAIDs
  • 5.5.1. NSAIDs market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Immune Response Modifiers
  • 5.6.1. Immune Response Modifiers market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. Photoenhancers
  • 5.7.1. Photoenhancers market estimates and forecasts 2021 to 2033 (USD Million)
• 5.8. Others
  • 5.8.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Actinic Keratosis Treatment Market: End Use Estimates & Trend Analysis

• 6.1. Global Actinic Keratosis Treatment Market: End Use Dashboard
• 6.2. Global Actinic Keratosis Treatment Market: End Use Movement Analysis
• 6.3. Global Actinic Keratosis Treatment Market by End Use, Revenue
• 6.4. Hospitals
  • 6.4.1. Diagnostic laboratories market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Private Clinics
  • 6.5.1. Private Clinics market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Homecare
  • 6.6.1. Homecare market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Actinic Keratosis Treatment Market: Regional Estimates & Trend Analysis by Product Type, Technology, and End Use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2025
  • 8.3.4. Almirall, S.A.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Brymill Cryogenic Systems
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Sun Pharmaceutical Industries Ltd.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Cortex Technology
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Galderma
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Ortho Dermatologics (Bausch Health Companies Inc.)
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. BIOFRONTERA Inc.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Hill Dermaceuticals, Inc
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Teva Pharmaceutical
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Viatris Inc.
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives